G01N 2333/7158
For chemokines
Official title: for chemokines
G01N2333/7158 (For chemokines) appears on 81 US grants and 179 published applications in this corpus.
Search patents in G01N- Granted patents
- 81
- Published applications
- 179
- Assignees
- 121
- Inventors
- 371
- Latest grant
- 9 Dec 2025
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2003 | 0 | 1 |
| 2004 | 0 | 0 |
| 2005 | 0 | 1 |
| 2006 | 0 | 0 |
| 2007 | 0 | 0 |
| 2008 | 0 | 2 |
| 2009 | 1 | 5 |
| 2010 | 2 | 6 |
| 2011 | 3 | 7 |
| 2012 | 3 | 11 |
| 2013 | 2 | 7 |
| 2014 | 5 | 9 |
| 2015 | 5 | 12 |
| 2016 | 5 | 7 |
| 2017 | 5 | 8 |
| 2018 | 6 | 18 |
| 2019 | 9 | 8 |
| 2020 | 8 | 16 |
| 2021 | 3 | 13 |
| 2022 | 5 | 7 |
| 2023 | 8 | 10 |
| 2024 | 5 | 9 |
| 2025 | 6 | 13 |
| 2026 | 0 | 9 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Anti-FAM19A5 antibodies and uses thereof9 Dec 2025US 12,492,246 B2Neuracle Science Co., Ltd.
- Azetidinyl-acetamides as CXCR7 inhibitors21 Oct 2025US 12,448,373 B2Amgen Inc.
- Methods and kits for evaluating clinical outcomes of autoimmune disease16 Sep 2025US 12,416,632 B2Singapore Health Services Pte Ltd
- System for detecting infection in synovial fluid12 Aug 2025US 12,385,909 B2CD Diagnostics, Inc.
- CXCR3 as epigenetic marker for the identification of inflammatory immune cells, in particular CD8+ memory t cells20 May 2025US 12,305,237 B2Precision for Medicine GmbH
- Anti-ccr8 antibodies and uses thereof17 Sep 2026US 2026/0274972 A1Gilead Sciences, Inc.
- Method for the selection of an ecobiological compound capable of increasing the skin tolerance threshold13 Aug 2026US 2026/0235581 A1
- Hydrogel bead-based platform for high throughput screening of immunomodulatory peptides and designer peptides for dendritic cells/macrophage reprogramming30 Jul 2026US 2026/0219276 A1The Hong Kong University of Science and Technology
- Implications of cxcr3 expression on myeloid cells for immunotherapy of cancer and myeloid-mediated diseases25 Jun 2026US 2026/0177546 A1The United States of America, as represented by the Secretary, Department of Health and Human
- Otic progenitor cell surface markers18 Jun 2026US 2026/0167930 A1WDI 2 ApS
Most cited
By later US patents
- Human CDR-grafted antibody and antibody fragment thereof19US 7,504,104 B2Kyowa Hakko Kogyo Co., Ltd. · 2009
- CCR3 inhibition for ocular angiogenesis and macular degeneration16US 8,008,092 B2University of Kentucky Research Foundation · 2011
- Depleting tumor-specific tregs15US 10,087,259 B1Memorial Sloan Kettering Cancer Center · 2018
- Human CDR-grafted antibody and antibody fragment thereof14US 7,842,797 B2Kyowa Hakko Kirin Co., Ltd. · 2010
- CXCR7 antagonists14US 9,169,261 B2ChemoCentryx, Inc. · 2015